New hope for kids with tough cancers: genetically engineered immune cells target tumors
NCT ID NCT03618381
Summary
This early-phase study is testing the safety and feasibility of a new treatment called CAR T-cell therapy for children and young adults whose solid tumors have come back or not responded to standard treatments. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer cells, and then infuse them back into the patient. The main goals are to find a safe dose, see if the cells can be reliably made, and understand the side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GERM CELL TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Seattle Children's Hospital
Seattle, Washington, 98105, United States
Conditions
Explore the condition pages connected to this study.